WM-8014: Selective KAT6A/B Inhibitor for Epigenetic Research

Executive Summary: WM-8014 is a potent, competitive inhibitor targeting KAT6A, KAT6B, KAT5, and KAT7 with nanomolar IC₅₀ values (8–342 nM) (APExBIO, product page). It acts at the acetyl-CoA binding site, mimicking substrate interactions and blocking histone acetyltransferase activity (RESTRICT-seq, DOI). WM-8014 induces cell cycle arrest and senescence via the p16^INK4A–p19^ARF pathway without causing broad cytotoxicity (APExBIO; RESTRICT-seq). Benchmark assays show reduction of hepatocyte proliferation and specific gene expression changes in vitro and in vivo. Its unique selectivity and workflow compatibility advance epigenetic drug discovery beyond standard KAT6A/B tools (see also related article).

Biological Rationale

KAT6A (MOZ) and KAT6B (MORF/QKF) are members of the MYST family of histone acetyltransferases. These enzymes regulate gene expression via acetylation of lysine residues on histone tails, modulating chromatin accessibility and transcriptional programs critical for cell proliferation, differentiation, and senescence. Overactivation of KAT6A/B is implicated in oncogenesis, particularly in solid tumors and hematological malignancies. Targeting these enzymes enables precise modulation of oncogene-induced senescence, a desirable outcome in cancer biology for halting uncontrolled growth while minimizing off-target cytotoxicity (RESTRICT-seq preprint).

Mechanism of Action of WM-8014

WM-8014 is a reversible, competitive inhibitor of the acetyl-CoA binding site in the MYST domain of KAT6A, KAT6B, KAT5, and KAT7. Its core acyl sulfonyl hydrazide moiety forms hydrogen bonds analogous to acetyl-CoA's diphosphate group, occupying the substrate-binding domain and preventing acetyl transfer. This results in potent inhibition of KAT6A (IC₅₀=8 nM), KAT6B (IC₅₀=28 nM), KAT5 (IC₅₀=224 nM), and KAT7 (IC₅₀=342 nM) in biochemical assays at 25°C, pH 7.5, buffered with 50 mM Tris-HCl (APExBIO).

Evidence & Benchmarks

• WM-8014 induces upregulation of Cdkn2a mRNA (encoding p16^INK4A and p19^ARF) in mouse embryonic fibroblasts after 24 h at 1 μM (RNA-seq, RESTRICT-seq, DOI).
• Treatment leads to downregulation of Cdc6 mRNA, a direct KAT6A target gene involved in DNA replication licensing, supporting cell cycle arrest (same study, DOI).
• In a zebrafish model of KRAS^G12V-driven liver hyperplasia, WM-8014 at 10 μM for 48 h reduces liver volume and hepatocyte S-phase entry by >60%, while not affecting normal liver growth (in vivo imaging, DOI).
• No generalized cytotoxicity observed in MEFs or zebrafish at concentrations up to 10 μM, as measured by viability and apoptotic markers (apoptosis assay, DOI).
• WM-8014 shows high plasma-protein binding in mouse plasma (>95%), limiting systemic exposure in murine models; alternate derivatives such as WM-1119 are recommended for in vivo mouse work (APExBIO).

Applications, Limits & Misconceptions

WM-8014 is optimized for mechanistic studies of selective histone acetyltransferase inhibition, cell cycle arrest assays, and oncogene-induced senescence induction. Researchers employ it to dissect epigenetic drug target pathways and validate functional dependencies in cancer biology (related article: This piece expands on precise assay integration and interpretation beyond protocol basics).

Common Pitfalls or Misconceptions

• Not a pan-HAT inhibitor: WM-8014 does not broadly inhibit all histone acetyltransferases; it is selective for MYST family members (KAT6A/B, KAT5, KAT7).
• Limited in vivo mouse application: Due to high plasma-protein binding, systemic exposures are unreliable in mouse models; use WM-1119 instead for such studies (APExBIO).
• Solubility constraints: WM-8014 is only soluble in water at 8–16 μM and is recommended for dissolution in DMSO (≥76.1 mg/mL); it is insoluble in ethanol and water at higher concentrations.
• No general cytotoxicity: Cellular senescence induction is not accompanied by widespread apoptosis or loss of viability at active concentrations.
• Storage caveats: WM-8014 stock solutions should not be stored long-term; -20°C is recommended for powder form only.

Workflow Integration & Parameters

WM-8014 is supplied by APExBIO (SKU A8779) for research use. It is typically dissolved in DMSO for cell-based and biochemical assays, with recommended working concentrations of 0.1–10 μM depending on target engagement and cell line. Cell cycle arrest can be measured via EdU incorporation, flow cytometry, or RNA-seq endpoints. RNA-seq in MEF cells treated at 1 μM for 24 h shows robust upregulation of senescence effectors and downregulation of DNA replication genes. For in vivo zebrafish work, 10 μM is applied for 48 h, with phenotypic readouts via live imaging (related article: This resource provides benchmark data and workflow tips; the present article details mechanism and cross-species data integration).

Conclusion & Outlook

WM-8014 represents a best-in-class tool for selective KAT6A/B inhibition, enabling targeted induction of oncogene-induced senescence without generalized cytotoxicity. Its competitive, reversible binding at the acetyl-CoA site allows for mechanistic dissection of epigenetic regulation in cancer and senescence biology. While high plasma-binding limits murine in vivo use, its profile is ideal for in vitro, ex vivo, and non-mammalian model systems. Future directions include use in high-throughput screens and integration with CRISPR-based functional genomics to uncover novel epigenetic dependencies. For in-depth technical details and procurement, visit the APExBIO WM-8014 product page.